Until prospective data are available, researchers recommend that patients with ER-low breast cancer “should be counseled regarding the potential benefit” of adjuvant endocrine therapy.

The PFS benefit with T-DXd was observed across all prespecified patient subgroups. Overall survival (OS) data were not mature ...

Q1 2025 Earnings Conference Call April 29, 2025 6:45 AM ETCompany ParticipantsAndy Barnett - Head of IRPascal Soriot ...

Daiichi Sankyo seeks Japanese approval for Enhertu to treat patients with HER2 positive metastatic solid tumours: Tokyo Friday, April 25, 2025, 09:00 Hrs [IST] Daiichi Sankyo has ...

Puma Biotechnology, Inc. , a biopharmaceutical company, announced that clinical data on neratinib were presented in a poster session at the American Association for Cancer Research (AACR) Annual ...

split between patients with both hormone receptor (HR)-positive and HR-negative disease. Coupled with that large target group of patients is stellar data with Enhertu (trastuzumab deruxtecan ...

Sacituzumab govitecan (SG), an ADC composed of a Trop-2 antibody coupled to SN-38 by a hydrolysable linker, has demonstrated activity and is approved in metastatic triple-negative breast cancer and in ...

Specifically, soy isoflavones can bind to estrogen receptors in the body and may actually cause a slight increase or decrease in estrogen.” It depends on the existing levels of estrogen hormones ...

Oral hormone therapy may benefit heart health in menopausal women. A new analysis of data from the Women's Health Initiative found that estrogen-based oral hormone therapy had a long-term beneficial ...

Removing EPO signaling in mouse liver tumors leads to tumor regression along with sensitivity to immunotherapy.